Hepatitis C Combination Therapy - MIGENIX initiates enrolment in Phase IIb HCV study of celgosivir+Pegetron

MIGENIX initiates enrolment in Phase IIb HCV study of celgosivir+Pegetron
InPharm.com - Celgosivir is a first-in-class, orally-administered, alpha glucosidase 1 inhibitor in development for the treatment of

GlobeImmune Relocates Corporate Headquarters
Pharma Live - LOUISVILLE, Colo., December 15, 2005 /PRNewswire/ -- GlobeImmune, Inc. today announced the relocation of its corporate headquarters to Louisville, Colorado. 1b trial for its second product, GI-5005, a Tarmogen for the treatment of

FDA grants final approval for Teva's Ribavirin
Israel Business Arena - peginterferon alfa-2a for treatment of adults with

Does Weight-based Ribavirin Dosing Increase Sustained Viral Response in Patients with
HIV and Hepatitis.com - HIVandHepatitis.com Coverage of Highlights from the 56th AASLD Nov 11 - 15, 2005 San Francisco, CA Top Articles This Week Does Weight-based Ribavirin Dosing Increase Sustained Viral Response in Patients with

GlobeImmune, Inc. Relocates Corporate Headquarters
BioSpace - 1b trial for its second product, GI-5005, a Tarmogen for the treatment of